Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details) $ in Thousands			3 Months Ended
	Apr. 25, 2017 USD ($) Target	Jul. 07, 2014 USD ($) Target Term	Mar. 31, 2022 USD ($)	Mar. 31, 2021	Dec. 31, 2021 USD ($)	Feb. 28, 2021 USD ($)	Mar. 17, 2017 Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Type of Revenue [Extensible List]			us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Deferred revenue			$ 178,801		$ 194,922
Bristol Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 91,300
Collaborative Arrangement | Bristol Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration target research term		2 years
Number of additional collaboration target | Target		2
Research terms			Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.
Extension of research term for each collaboration target		1 year
Upfront payment received	$ 200,000	$ 50,000
Contingent milestone payments receivable						$ 1,779,000
Number of research targets selected | Target	8
Total transaction price		272,800
Upfront payment received		250,000
Research and development service fees		10,800
Milestone payment received		$ 12,000
Estimated research service termination date		Apr. 25, 2025
Deferred revenue			$ 91,300		$ 98,800
Collaborative Arrangement | Maximum | Bristol Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of oncology target | Target		4
Number of collaboration target | Target		2
Period of nomination of additional target from effective date		5 years
Times of increments for extended collaboration target research time | Term		3
Contingent milestone payments receivable	$ 3,586,000	$ 1,192,000
Collaborative Arrangement | Maximum | Bristol Myers Squibb Company | Each Of Two Additional Targets
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent milestone payments receivable		$ 25,000
Collaboration and License Agreement | Maximum | Bristol Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of additional collaboration target | Target							8